Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.

Hassan MZ. et al, (2025), The Lancet regional health. Southeast Asia, 33

Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).

Pesonel E. et al, (2025), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Ebola disease: bridging scientific discoveries and clinical application.

Rojek A. et al, (2024), The Lancet. Infectious diseases

Embedding treatment in stronger care systems

Rojek A. et al, (2024), The Lancet Infectious Diseases

Presentation and Outcomes of Lassa Fever in Children in Nigeria: A Prospective Cohort Study (LASCOPE)

Duvignaud A. et al, (2024), Journal of the Pediatric Infectious Diseases Society, 13, 513 - 522

Group sequential designs for clinical trials when the maximum sample size is uncertain

Yarahmadi A. et al, (2024), Statistics in Medicine, 43, 4667 - 4683

Community Involvement in an Outbreak-One Year on for Mpox.

Cheyne A. et al, (2024), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 79, 278 - 280

Nipah virus disease: what can we do to improve patient care?

Hassan MZ. et al, (2024), The Lancet Infectious Diseases, 24, e463 - e471

Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae.

Gonçalves BP. et al, (2024), Epidemiology (Cambridge, Mass.), 35, 368 - 371

High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.

Peto L. et al, (2024), Lancet (London, England), 403, 1339 - 1340

Mpox: The alarm went off. Have we gone back to sleep?

Olliaro P. et al, (2024), PLOS Neglected Tropical Diseases, 18, e0011871 - e0011871

The burden and dynamics of hospital-acquired SARS-CoV-2 in England

Cooper BS. et al, (2023), Nature, 623, 132 - 138

A multi-country analysis of COVID-19 hospitalizations by vaccination status

Gonçalves BP. et al, (2023), Med, 4, 797 - 812.e2

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Pairo-Castineira E. et al, (2023), Nature, 617, 764 - 768

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

Kartsonaki C. et al, (2023), International Journal of Epidemiology, 52, 355 - 376

Randomised controlled trials for mpox in endemic countries.

Rojek A. et al, (2023), The Lancet. Infectious diseases, 23

Facilitating participation in clinical trials during pregnancy.

Vousden N. et al, (2023), BMJ (Clinical research ed.), 380

Engaging the community during PLATINUM: A randomised controlled trial of tecovirimat in non-hospitalised mpox patients

Cheyne A. et al, (2023), TROPICAL MEDICINE & INTERNATIONAL HEALTH, 28, 388 - 388

MOSAIC: A cohort study of human mpox virus disease.

Pesonel E. et al, (2023), Wellcome open research, 8

An evaluation of global Chikungunya clinical management guidelines: A systematic review

Webb E. et al, (2022), eClinicalMedicine, 54, 101672 - 101672

Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.

Peto L. et al, (2022), Advances in biological regulation, 86

Load More